Most Read Articles
Kathlin Ambrose, 12 Nov 2015
The outcome for patients experiencing out-of-hospital sudden cardiac arrest (OSCA) remains very poor in Malaysia. Local data shows that return of spontaneous circulation in OSCA patients stands at 17.4 percent, while survival to ward is a mere 4.3 percent. [Med J Malaysia 2008; 63:4–8]
Tristan Manalac, 2 days ago
Contrary to conventional knowledge, consumption of dairy products appears to reduce the risk of major cardiovascular disease events and mortality, according to a recent multinational study.
Pearl Toh, 17 Sep 2018
Lifestyle interventions incorporating diet and exercise slash the need for antihypertensive medications by more than half among overweight or obese adults with high blood pressure (BP), according to a secondary analysis of the ENCORE trial presented at the Joint Hypertension 2018 Scientific Sessions.
Christina Lau, 31 Aug 2018

Daily low-dose aspirin is not beneficial for primary prevention of cardiovascular (CV) events in patients with diabetes or moderate CV risk, according to results of the ASCNED and ARRIVE trials reported at the European Society of Cardiology (ESC) Congress 2018.

Serum CRP, endothelin levels high in hypertensive patients

06 Aug 2018

In patients with uncontrolled blood pressure and severe hypertension, microvascular dysfunction is more pronounced and serum C-reactive protein (CRP) and endothelin levels are elevated, a recent study has found.

Using nailfold videocapillaroscopy, researchers evaluated microcirculatory parameters in 25 patients with resistant hypertension (RH; mean age 55.5±10.2 years), 25 patients with mild-to-moderate hypertension (MMH; mean age 55.0±9.8 years) and 25 normotensive controls (mean age 39.4±15.8 years).

Median serum CRP levels were significantly elevated in RH and MMH patients relative to the controls (0.36 and 0.21 vs 0.06 ng/dL; p=0.005), but no significant difference was observed between the two hypertensive groups. Levels of other inflammatory biomarkers such as adiponectin and endothelin were comparable among the three groups.

Upon subgroup analyses, individuals who were not on statin medication showed increased median endothelin levels, which reached statistical significance in the MMH and RH groups compared with the controls (26.7 and 24.3 vs 15.09 pg/dL; p=0.0001 and p=0.003, respectively).

Moreover, median serum CRP was significantly higher in the RH group than in the MMH and control groups (0.45 vs 0.17 and 0.06 ng/dL; p=0.04), while red blood cell velocity was significantly lower than in normotensive controls (0.91 vs 0.95; p=0.01).

Restricting the analysis to hypertensive participants, researchers showed that nonuse vs use of statins led to significantly higher median serum endothelin levels in both the RH (24.3 vs 16.5 pg/dL) and MMH (26.7 vs 13.1 pg/dL; p<0.01) groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Kathlin Ambrose, 12 Nov 2015
The outcome for patients experiencing out-of-hospital sudden cardiac arrest (OSCA) remains very poor in Malaysia. Local data shows that return of spontaneous circulation in OSCA patients stands at 17.4 percent, while survival to ward is a mere 4.3 percent. [Med J Malaysia 2008; 63:4–8]
Tristan Manalac, 2 days ago
Contrary to conventional knowledge, consumption of dairy products appears to reduce the risk of major cardiovascular disease events and mortality, according to a recent multinational study.
Pearl Toh, 17 Sep 2018
Lifestyle interventions incorporating diet and exercise slash the need for antihypertensive medications by more than half among overweight or obese adults with high blood pressure (BP), according to a secondary analysis of the ENCORE trial presented at the Joint Hypertension 2018 Scientific Sessions.
Christina Lau, 31 Aug 2018

Daily low-dose aspirin is not beneficial for primary prevention of cardiovascular (CV) events in patients with diabetes or moderate CV risk, according to results of the ASCNED and ARRIVE trials reported at the European Society of Cardiology (ESC) Congress 2018.